Remission status in persistent depressive disorder following acute treatment with psychotherapy plus medication or medication alone: A 2-year naturalistic follow-up.
Carly Yasinski, Tianwen Ma, Michael E Thase et al.
✦ AI-curated · Sources linked
In 30 seconds
This observational study followed patients with persistent depressive disorder (PDD) for two years after acute treatment with psychotherapy plus medication or medication alone. Among 323 participants, 203 (62.8%) experienced major depressive episode (MDE) recurrences, with no significant differences between treatment groups. The study highlights the lack of long-term benefits of cognitive behavioral analysis system of psychotherapy (CBASP) compared to other treatments.
Key findings
- 62.8% of participants met criteria for current MDE during follow-up.
- No significant differences in recurrence rates among treatment groups: BSP 65.3%, CBASP 60.2%, MEDS 63.6%.
- Remission after acute treatment was associated with lower recurrence risk.
Why it matters
Understanding the long-term outcomes of treatments for persistent depressive disorder is crucial for clinicians to make informed decisions about patient care and to manage expectations regarding treatment efficacy.